People channel feed

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

Subscribe to Endpoints News
Terry Fry (Sana Biotechnology)

Sana's Ter­ry Fry leads new $200M cell and gene ther­a­py in­sti­tute at Uni­ver­si­ty of Col­orado

A new cell and gene therapy center is taking shape in the Rockies, one that hopes to raise hundreds of millions of dollars in the next few years. And they’re getting a prominent biotech leader to kick things off.

The University of Colorado’s Anschutz Medical Campus established the new Gates Institute, the school announced Wednesday, with the goal of raising $200 million in the next five years. Terry Fry, the well-known hematologist and head of T cell therapeutics at Sana, will step in as the institute’s first executive director.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,200+ biopharma pros reading Endpoints daily — and it's free.

Clay Siegall, Seagen CEO (Life Science Washington via YouTube)

UP­DAT­ED: Ar­rest re­port, court docs out­line mul­ti­ple spouse abuse al­le­ga­tions against Seagen founder Clay Sie­gall

New information has emerged detailing the events that led to the April 23 arrest of Seagen CEO Clay Siegall and a May 2 temporary restraining order against him, according to documents obtained by Endpoints News.

Around 3 a.m. local time on April 23, Siegall’s wife and a witness called police after he allegedly pushed her to the ground, and he was brought to jail hours later on a charge of fourth degree domestic violence gross misdemeanor, per police records from that morning. The records, as well as a restraining order and jail call logs, lay out the allegations against one of the highest-profile CEOs in biotech, who founded Seagen in the late 1990s and has built it into a $22 billion drug developer that led the ADC R&D field. Siegall was also one of the most richly compensated pharma executives in 2021, pulling in $18.1 million.

Thibaut Mongon, incoming CEO of J&J's spin-off consumer health company

J&J taps a long­time vet to run its con­sumer health spin­off ahead of next year's sep­a­ra­tion

J&J is turning to longtime insiders in the executive ranks to head up its consumer division, once the company completes its spinout: Thibaut Mongon, who will serve as CEO, and Paul Ruh, who will operate as CFO of the yet-to-be-named consumer health company.

Mongon has been on the payroll for the past 20 years, rising through the ranks since joining in 2000, according to his LinkedIn page. He reached the heights of executive vice president and worldwide chairman of consumer health at J&J and has been in that position since 2019.

Jorge Gomez, Moderna ex-CFO

Mod­er­na's new CFO out af­ter for­mer em­ploy­er un­veils in­ter­nal au­dit­ing in­ves­ti­ga­tion

Just as quickly as he started, the new CFO at Moderna has been shown the door after a single day on the job.

Jorge Gomez was out in a day after his former employer, Dentsply Sirona, said it was in an ongoing internal investigation by the audit committee, according to an SEC filing. The audit is investigating Dentsply Sirona’s “use of incentives to sell products to distributors in the third and fourth quarters of 2021, and whether those incentives were appropriately accounted for and the impact of those sales was adequately disclosed in the Company’s periodic reports filed with the Securities and Exchange Commission.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,200+ biopharma pros reading Endpoints daily — and it's free.

Usama Malik

For­mer Im­munomedics CFO Us­ama Ma­lik in­dict­ed for al­leged­ly giv­ing ex-girl­friend in­sid­er in­fo

Legal trouble is mounting higher for Usama Malik, the former Immunomedics CFO accused of sharing insider information with his then-girlfriend and a number of relatives.

Malik was indicted Wednesday morning on three counts of insider trading, securities fraud and securities fraud conspiracy, the US Department of Justice announced.

The former CFO spent nearly four years at Immunomedics, helping steer the company to a $21 billion buyout by Gilead back in 2020. The ink was barely dry before he jumped over to the helm at precision oncology company Fore Bio — but that didn’t last long.

Joseph Kim (Andrew Harnik/AP Images)

In­ovio's long­time CEO is out as Covid vac­cine lag­gard throws in the tow­el on PhI­II, piv­ots to boost­er

Joseph Kim, the longtime CEO who’s become almost synonymous with Inovio, is leaving the beleaguered company.

Stepping down to make room for Jacqueline Shea — who first joined Inovio as COO in 2019 — Kim leaves behind a legacy of boisterous claims and promises about DNA vaccines over decades and a habit of capitalizing on pandemics but no approved product to show for it.

Shea will be overseeing a change in direction as Inovio, a laggard in the Covid-19 vaccine race, shutters a Phase III trial in favor of a booster strategy.

Paul Hastings, Nkarta CEO and BIO chair

'Front and cen­ter': In­dus­try lead­ers call for re­sponse to Supreme Court abor­tion case draft

Biotech industry leaders want the drug development world to stand up and ensure employees have access to abortions after a draft ruling last week revealed the nation’s highest court might overturn a nearly five-decade-old ruling, known by two names: Roe v. Wade.

“We have to make noise, for one thing, which is effective, but also encourage people to take some sort of action,” Paul Hastings told Endpoints News. Last week, the Nkarta CEO and BIO chair called on his fellow biotech companies to help pay for travel expenses for employees in states hindering access to reproductive health.

As biotech mar­ket re­mains chilly, Longeveron CEO steps down af­ter 18-month run

The Longeveron CEO who helped take the biotech public is now set to resign.

Geoff Green, Longeveron’s chief executive since November 2020, will step down effective June 1 to pursue new opportunities, the company announced Monday afternoon. In his place, current CMO Chris Min will serve as interim CEO while Longeveron conducts a search for a permanent chief.

Green will remain a consultant for an undetermined time to help ensure a smooth transition, the company added. Shares $LGVN were down about 5% in post-market trading. He joins a cadre of biotech executives leaving their posts in the wake of a bear market that continues to batter the sector.

Tillman Gerngross (Photo by Craig F. Walker/The Boston Globe via Getty Images)

Till­man Gern­gross pass­es the Adimab ba­ton af­ter 15 years, mov­ing from CEO to ex­ec­u­tive chair­man role

A new era is unfolding at Adimab.

Fifteen years after he co-founded the antibody discovery shop, Tillman Gerngross is stepping down as CEO — handing the reins to Philip Chase, general counsel. Stepping away from day-to-day operations, the company noted he will now move to the strategic role of executive chairman of the board.

It’s the second departure for Gerngross within the past few months. Back in February, the longtime Dartmouth professor resigned from the CEO post at Adagio, the Covid-focused Adimab spinout.

Clay Siegall, Seagen CEO (Dimitrios Kambouris/Getty Images for Gabrielle's Angel Foundation)

Seagen CEO Clay Sie­gall was placed on leave af­ter an April 23 ar­rest for do­mes­tic vi­o­lence gross mis­de­meanor

Clay Siegall was placed on leave from his posts as CEO and chairman of prominent Seattle-area biotech Seagen after an arrest by the Edmonds Police Department on April 23.

At 3:41 a.m. local time on April 23, police were dispatched to Siegall’s home, where he was arrested on charge of 4th degree assault domestic violence gross misdemeanor, the police department’s public information officer confirmed to Endpoints News. Siegall had a court appearance the next day, the officer said, noting the investigation is now in the court’s hands.